ignite international brands ltd annual report hicarquitectura.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hicarquitectura.com Daily Mail and Mail on Sunday newspapers.
Kojin Therapeutics has raised $60 million to use iron-dependent cell death to treat drug-resistant cancer. The series A round positions the biotech to build on the work its scientific founders did at institutions including Harvard University and Dana-Farber Cancer Institute.
Published: Jun 09, 2021 By Mark Terry
Kojin Therapeutics
launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
The approach came out of the
laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis.
The Red Wing-based company created an app that helped users save and donate money to charities. Now, one of the nation s largest credit unions will help promote it.
Red Wing MN and East Lansing MI (PRWEB) May 27, 2021 Live.Give.Save. Inc., a women-founded fintech company that created the first personal finance mobile